Redwood Pharma AB (publ) Quarterly report January–March 2022
May 10, 2022 12:30 pmNASDAQ FIRST NORTH GROWTH MARKET: REDW.ST, REDWOODPHARMA.COM 1 January – 31 March 2022 The company’s net revenue for the period... View Article
NASDAQ FIRST NORTH GROWTH MARKET: REDW.ST, REDWOODPHARMA.COM 1 January – 31 March 2022 The company’s net revenue for the period... View Article
(Stockholm, Sweden, May 5, 2022) Redwood Pharma AB (publ) today announces that the first patient has been included in the company’s... View Article
Redwood Pharma will participate in the BioStock Life Science Summit in Lund and in Stockholm. CEO Martin Vidaeus will update... View Article
Redwood Pharma has received approval from the Austrian Federal Office for Safety in Health Care (BASG) to initiate the clinical trial... View Article
The causes of dry eye disease and degrees of severity in patients vary widely. Today there is no single silver... View Article
Based on the IntelliGel platform which delivers moisturizing water and protection for the eye, RP501 is Redwood Pharma’s developmental hydrogel... View Article
NASDAQ FIRST NORTH GROWTH MARKET: REDW.ST, redwoodpharma.se 1 January – 31 December 2021 The company’s net revenue for the period... View Article
Redwood Pharma has received approval from an Austrian ethics committee for the start of a clinical trial of RP501. This... View Article
Redwood Pharma will be attending two of the leading international conferences in ophthalmology and biotechology during 2022. The goals of... View Article